



Entry into clinical phase: clonidine Lauriad[®] into phase II and AMEP[™] into phase I.

With fentanyl Lauriad[®], three products entered clinical phase in 2009.

Paris, December 15, 2009 – BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announces the approval from the French Drug Agency (AFFSSaPS) to enter Phase II clinical trial for clonidine Lauriad[®] in radiotherapy and chemotherapy-induced oral mucositis and the approval from Danish and Slovene Agencies to enter Phase I clinical trial for AMEP[™] in invasive melanoma.

Clonidine Lauriad[®] uses the innovative muco-adhesive technology validated with Loramyc[®] and more recently with acyclovir Lauriad[®]. This new product is dedicated to the prevention and the treatment of radiotherapy and chemotherapy-induced oral mucositis in cancer patients. Clonidine Lauriad[®] is part of the supportive care pipeline BioAlliance Pharma is building. This product presents the opportunity to satisfy an unmet medical need. Patent application has been filed.

AMEP[™], anti-invasive biotherapy, is dedicated to metastatic and invasive melanoma, an advanced skin cancer refractory to most treatments. Its original mechanism of action targets specific receptors involved in tumor growth and in tumor angiogenesis. This project is supported by OSEO (the French state innovation agency) which finances technological breakthrough projects and has been granted €6.4 million to participate in its clinical development.

In both trials, the first patients should be recruited early 2010.

« With fentanyl Lauriad[®], clonidine Lauriad[®] and AMEP[™], BioAlliance Pharma's Teams have fulfilled our objective to bring these three products into clinical phase in 2009 while using our industrial know-how of Lauriad[®] mucoadhesive technology, and confirming significant progress in the development of our new cancer chemical entities », comments Dominique Costantini, President and CEO of BioAlliance Pharma.

About BioAlliance Pharma

As a preferred partner for hospital-based specialists, BioAlliance Pharma is a company which develops and markets innovative products in France, especially in the fields of opportunistic infections and chemotherapy complications. In areas where medical needs are insufficiently met, our targeted approaches help overcome drug resistance and improve patient health & quality of life. BioAlliance Pharma's ambition is to become a leading player in these fields by coupling innovation to patient needs.

For more information, visit the BioAlliance Pharma web site at www.bioalliancepharma.com.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2008 Reference Document filed with the AMF on April 7, 2009, which is available on the AMF website (<http://www.amf-france.org>) or on BioAlliance Pharma S.A.'s website (<http://www.bioalliancepharma.com>).

BioAlliance Pharma SA

Dominique Costantini, President and CEO

Tel.: +33 1 45 58 76 01

dominique.costantini@bioalliancepharma.com

Nicolas Fellmann, CFO

Tel.: +33 1 45 58 71 00

nicolas.fellmann@bioalliancepharma.com

ALIZE RP

Caroline Carmagnol

Tel.: +33 6 64 18 99 59

caroline@alizerp.com